CELLDEX THERAPEUTICS INC (CLDX) Stock Income Statement
NASDAQ:CLDX - Nasdaq - US15117B2025 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 7.56M | 7.02M | 6.88M | 2.36M | 4.65M | |||
| Operating Expenses | 224.77M | 202.10M | 148.93M | 102.59M | 72.39M | |||
| Research and Development | 184.50M | 163.55M | 118.01M | 82.26M | 53.31M | |||
| Selling, General, and Administrative Expenses | 40.27M | 38.55M | 30.91M | 27.20M | 20.49M | |||
| Operating Income | -217.21M | -195.08M | -142.04M | -100.23M | -67.74M | |||
| Interest Income/Expense | 38.36M | 37.22M | 13.11M | 2.91M | 510.00K | |||
| Non Recurring Items | N/A | 0.00 | -12.50M | -15.00M | -3.50M | |||
| Income Before Taxes | -178.85M | -157.86M | -141.43M | -112.33M | -70.74M | |||
| Income Tax | N/A | 0.00 | 0.00 | 0.00 | -230.00K | |||
| Net Income | -178.85M | -157.86M | -141.43M | -112.33M | -70.51M | |||
| EBITDA | -213.94M | -191.90M | -139.03M | -97.33M | -64.67M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -2.70 | -2.45 | -2.92 | -2.40 | -1.64 | |||
| Non GAAP EPS | -2.70 | -2.45 | -2.91 | -2.21 | -1.64 | |||
| Statistics | ||||||||
| Profit Margin | -2366.07% | -2248.76% | -2054.76% | -4759.75% | -1516.34% | |||
| Operating Profit Margin | -2873.52% | -2778.89% | -2063.66% | -4247.03% | -1456.77% | |||
All data in USD